Patents by Inventor John E. Donello

John E. Donello has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD OF ACTIVATING REGULATORY T CELLS WITH ALPHA-2B ADRENERGIC RECEPTOR AGONISTS
    Publication number: 20170079956
    Abstract: Disclosed herein is a method of upregulating regulatory T cells, and treating diseases that would benefit from such upregulation, by administering an alpha-2 receptor agonist.
    Type: Application
    Filed: December 7, 2016
    Publication date: March 23, 2017
    Inventors: Daniel W. Gil, John E. Donello, Veena Viswanath, Lauren M.B. Luhrs
  • Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators
    Patent number: 9579307
    Abstract: The present invention relates to novel amide derivatives of N-urea substituted amino acids, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor like-1 (FPRL-1) receptor.
    Type: Grant
    Filed: April 26, 2016
    Date of Patent: February 28, 2017
    Assignee: Allergan, Inc.
    Inventors: Richard L. Beard, Tien T. Duong, John E. Donello, Veena Viswanath, Michael E. Garst
  • SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS
    Publication number: 20170050925
    Abstract: The present invention relates to novel sulfur derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.
    Type: Application
    Filed: September 10, 2014
    Publication date: February 23, 2017
    Inventors: HAIQING YUAN, RICHARD L. BEARD, MICHAEL E. GARST, JOHN E. DONELLO, XIAOXIA LIU, VEENA VISWANATH
  • Benzofuran-2-sulfonamides derivatives as chemokine receptor modulators
    Patent number: 9550746
    Abstract: The present invention relates to novel benzofuran-2-sulfonamide derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.
    Type: Grant
    Filed: January 5, 2015
    Date of Patent: January 24, 2017
    Assignee: ALLERGAN, INC.
    Inventors: Haiqing Yuan, Richard L. Beard, Xiaoxia Liu, John E. Donello, Veena Viswanath, Michael E. Garst
  • Method of activating regulatory T cells with alpha-2B adrenergic receptor agonists
    Patent number: 9545394
    Abstract: Disclosed herein is a method of upregulating regulatory T cells, and treating diseases that would benefit from such upregulation, by administering an alpha-2 receptor agonist.
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: January 17, 2017
    Assignee: Allergan, Inc.
    Inventors: Daniel W. Gil, John E. Donello, Veena Viswanath, Lauren M. B. Luhrs
  • Alpha adrenergic receptor modulators
    Patent number: 9522150
    Abstract: Compounds are described herein useful for treating diseases and conditions by modulation of one or more alpha adrenergic receptor. The compounds can include a naphthalene, a quinoline, a benzimidazole or an isoquinoline as a core structure. Methods of making, using and formulating these compounds are described.
    Type: Grant
    Filed: April 7, 2015
    Date of Patent: December 20, 2016
    Assignee: Allergan, Inc.
    Inventors: Ken Chow, Liming Wang, Wenkui K. Fang, Evelyn G. Corpuz, Santosh C. Sinha, Daniel W. Gil, Mohammad I. Dibas, John E. Donello
  • ESTER PRO-DRUGS OF [3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL] METHANOL FOR TREATING SKIN DISEASES AND CONDITIONS
    Publication number: 20160354346
    Abstract: The present invention relates to method for treating skin diseases and skin conditions in a subject in need of such treatment, which comprises administering a therapeutically effective amount of a composition comprising ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol, or enantiomers thereof, pharmaceutical compositions containing them and their use as pharmaceuticals.
    Type: Application
    Filed: August 18, 2016
    Publication date: December 8, 2016
    Inventors: Mohammed I. Dibas, Daniel W. Gil, John E. Donello, Ken Chow, Liming Wang, Michael E. Garst
  • Compositions for treating cognitive disorders
    Patent number: 9492543
    Abstract: Disclosed herein is a pharmaceutical composition comprising a cholinesterase inhibitor and compound of the following formula: The composition is effective for treating cognitive disorders, and methods of treating such disorders using the composition are also disclosed.
    Type: Grant
    Filed: October 11, 2012
    Date of Patent: November 15, 2016
    Assignee: Allergan, Inc.
    Inventors: Ursula V. Staubli, John E. Donello
  • PHARMACEUTICAL COMPOSITIONS COMPRISING 4-[1-(2,3-DIMETHYLPHENYL)ETHYL]-3HIMIDAZOLE DERIVATIVES FOR TREATING RETINAL DISEASES
    Publication number: 20160303083
    Abstract: The present invention relates to pharmaceutical compositions, containing 4-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazole, (S) 4 [1-(2,3-dimethylphenyl)ethyl]-1H-imidazole or (S) [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl]methanol, their use as pharmaceuticals for the treatment of retinal diseases, for retinal neuroprotection and vision enhancement.
    Type: Application
    Filed: June 27, 2016
    Publication date: October 20, 2016
    Inventors: Mohammed I. Dibas, John E. Donello, Daniel W. Gil
  • SUBSTITUTED 6, 7-DIALKOXY-3-ISOQUINOLINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASE 10 (PDE 10A)
    Publication number: 20160264549
    Abstract: The invention relates to compounds of the formula or a pharmaceutically acceptable salt thereof, wherein R?, R1 through R7 and Ar are as defined herein. These compounds are useful as inhibitors of phosphodiesterase 10 (PDE10A) which are useful in treating central nervous system diseases such as psychosis and also in treating, for example, obesity, type II diabetes, metabolic syndrome, glucose intolerance, pain and ophthalmic diseases.
    Type: Application
    Filed: October 16, 2015
    Publication date: September 15, 2016
    Applicant: EXONHIT THERAPEUTICS, SA
    Inventors: Bertrand Leblond, Thierry Taverne, Cedric Chauvignac, Eric Beausoleil, Anne-Sophie Casagrande, Laurent Desire, Matthew P. Pando, John E. Donello, Rong Yang
  • Derivatives of N-urea substituted amino acids as formyl peptide receptor modulators
    Patent number: 9428549
    Abstract: The present invention relates to derivatives of N-urea substituted amino acids, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide 2 receptor.
    Type: Grant
    Filed: July 10, 2014
    Date of Patent: August 30, 2016
    Assignee: Allegran, Inc.
    Inventors: Richard L. Beard, Tien T. Duong, John E. Donello, Veena Viswanath, Michael E. Garst
  • AMIDE DERIVATIVES OF N-UREA SUBSTITUTED AMINO ACIDS AS FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS
    Publication number: 20160235711
    Abstract: The present invention relates to novel amide derivatives of N-urea substituted amino acids, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor like-1 (FPRL-1) receptor.
    Type: Application
    Filed: April 26, 2016
    Publication date: August 18, 2016
    Inventors: Richard L. Beard, Tien T. Duong, John E. Donello, Veena Viswanath, Michael E. Garst
  • Benzofuran-2-sulfonamides pyridine derivatives as chemokine receptor modulators
    Patent number: 9416120
    Abstract: The present invention relates to novel benzofuran-2-sulfonamide pyridine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.
    Type: Grant
    Filed: July 17, 2014
    Date of Patent: August 16, 2016
    Assignee: Allergan, Inc.
    Inventors: Haiqing Yuan, Richard L. Beard, Michael E. Garst, Xiaoxia Liu, John E. Donello, Veena Viswanath
  • NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS
    Publication number: 20160228407
    Abstract: The present invention relates to novel bis-sulfonamide derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.
    Type: Application
    Filed: September 8, 2015
    Publication date: August 11, 2016
    Inventors: Haiqing Yuan, Richard L. Beard, Michael E. Garst, Xiaoxia Liu, John E. Donello, Veena Viswanath
  • 1-aryl-1-hydroxy-2,3-diamino-propyl amines, 1-heteroaryl-1-hydroxy-2,3-diamino-propyl amines and related compounds having analgesic and/or immuno stimulant activity
    Patent number: 9399628
    Abstract: Compounds of the formula where the variables have the meaning defined in the specification have analgesic and/or immunostimulant effect in mammals.
    Type: Grant
    Filed: July 24, 2013
    Date of Patent: July 26, 2016
    Assignee: Allergan, Inc.
    Inventors: Bertrand Leblond, Eric Beusoleil, Thierry Taverne, John E. Donello
  • Sulfur derivatives as chemokine receptor modulators
    Patent number: 9371278
    Abstract: The present invention relates to novel sulfur derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.
    Type: Grant
    Filed: April 10, 2014
    Date of Patent: June 21, 2016
    Assignee: Allergan, Inc.
    Inventors: Haiqing Yuan, Richard L. Beard, Xiaoxia Liu, John E. Donello, Veena Viswanath, Michael E. Garst
  • METHOD OF ACTIVATING REGULATORY T CELLS WITH ALPHA-2B ADRENERGIC RECEPTOR AGONISTS
    Publication number: 20160158199
    Abstract: Disclosed herein is a method of upregulating regulatory T-cells, and treating diseases that would benefit from such upregulation, by administering an alpha-2 receptor agonist.
    Type: Application
    Filed: February 12, 2016
    Publication date: June 9, 2016
    Inventors: Daniel W. Gil, John E. Donello, Veena Viswanath, Lauren M.B. Luhrs
  • PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE FOR TREATING SKIN DISEASES AND CONDITIONS
    Publication number: 20160151349
    Abstract: The present invention relates to a method for treating skin diseases and skin conditions in a patient in need thereof which comprises of administering a therapeutically effective amount of a pharmaceutical composition comprising a therapeutically effective amount of 7-(1H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline, or its individual enantiomers or the tautomers thereof, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: February 4, 2016
    Publication date: June 2, 2016
    Inventors: Mohammed I. Dibas, Edward C. Hsia, John E. Donello, Daniel W. Gil
  • Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators
    Patent number: 9351948
    Abstract: The present invention relates to novel amide derivatives of N-urea substituted amino acids, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor like-1 (FPRL-1) receptor.
    Type: Grant
    Filed: January 29, 2015
    Date of Patent: May 31, 2016
    Assignee: Allergan, Inc.
    Inventors: Richard L. Beard, Tien T. Duong, John E. Donello, Veena Viswanath, Michael E. Garst
  • Sulfur derivatives as chemokine receptor modulators
    Patent number: 9328067
    Abstract: The present invention relates to novel sulfur derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: May 3, 2016
    Assignee: ALLERGAN, INC.
    Inventors: Haiqing Yuan, Richard L. Beard, Xiaoxia Liu, John E. Donello, Veena Viswanath, Michael E. Garst